Annie Schmidt
Associate
Dan Chiorean
Associate
Stuart E. Des Roches
Member
stuart@odrlaw.com

Mr. Des Roches' legal career has been closely tied to the application of the antitrust laws to the pharmaceutical industry since the early 1990's. This body of work includes being on the team that filed and litigated the first Hatch-Waxman "reverse payment" antitrust cases in the late 1990's on behalf of direct purchasers against makers of branded and generic pharmaceutical drug products. Since that time, Mr. Des Roches has dedicated a large portion of his legal career to this area of competition law in the hope of ensuring that the pharmaceutical marketplace is one of full and fair competition between makers of branded and generic drugs to drive innovation and competitive prices as contemplated by the Hatch-Waxman Act of 1984 and the Antitrust Laws. In addition to the early and more recent "reverse payment" cases, Mr. Des Roches has also been involved on behalf of direct purchasers in challenging for the first time several additional practices in the pharmaceutical industry that improperly delay or impede the market entry of less-expensive generic versions of brand name drugs, such as the filing of sham citizen petitions with FDA, the filing sham patent lawsuits in federal courts, and product hopping.

Many of these cases have been litigated up to the courthouse steps or into trial prior to resolution, while others continue to be litigated. Mr. Des Roches served as the lead trial lawyer for the class of direct purchasers in In re Tricor Direct Purchaser Antitrust Litigation, which resulted in the largest settlement at that time of a Hatch-Waxman antitrust case ($250,000,000) after commencement of trial. In addition, other notable cases in which Mr. Des Roches has been intimately involved from start to finish include: King Drug v. Cephalon, et al. (settlement with 3 of 5 defendants for $512,000,000); In re Neurontin ($190,000,000 recovery); In re Buspirone ($220,000,000 recovery); In re Relafen ($175,000,000 recovery); In re Cardizem CD ($110,000,000 recovery); In re Prograf ($98,000,000 recovery); In re Remeron ($75,000,000 recovery); In re Terazosin Hydrochloride ($72,500,000 recovery).

Notable on-going pharmaceutical antitrust cases include: In re AndroGel; In re Lamictal; In re K-Dur; In re: Suboxone; In re Namenda; In re Niapsan; In re Aggrenox; In re Opana Antitrust Litig.

Mr. Des Roches has also been involved in applying the antitrust laws to the others aspects of the healthcare industry. He served as trial counsel with the firm's member Mr. Kelly in Natchitoches Parish Hospital Service District, et al. v. Tyco Healthcare, et al., which settled for $32,500,000 several weeks into trial.

Born, New Orleans, Louisiana, August 12, 1966. Admitted to numerous United States District Courts and Courts of Appeals, and the United States Supreme Court. University of New Orleans (B.A., 1989), and Tulane University School of Law (J.D., 1992). Member, New Orleans, Louisiana, and American Bar Associations, and the United States Supreme Court Historical Society.

Suite 2020, Poydras Center
650 Poydras Street
New Orleans, Louisiana 70130
Telephone: 504-522-0077
Fax: 504-522-0078

5496 Hall Road
P.O. Box 523
Hahira, Georgia 31632
Telephone: 229-794-3412
Fax: 229-794-3544